Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Supplementary Table 1 Reasons for CT-P13 withdrawal due to adverse events Reason for CT-P13 withdrawal Unspecified adverse events Infection Skin rash Fatigue Nausea Arthralgia Parestesia Depression Myalgia Oedema Chest pain or uneasy chest Headache Fever or flu-like symptoms Diarrhea Unspecified infusion reaction Sinuitis Insomnia Allergic reaction, unspecified Hypertension Polycythemia Psoriasis Demyelinating disease Herpes zoster Hypoglycemia Dyspnoe Total 57 events were observed in 37 patients Number of events 10 6 4 4 3 3 3 2 2 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 57 Supplementary Table 2 Baseline demographics and clinical characteristics (by January 2014) of the comparison INX group stratified by diagnosis Comparison group of INX treated patients Number of patients, n Women, n (%) Age, years Number of comorbidities ≥ 1, n (%)# Biological treatment number, INX Concomitant methotrexate, n (%) Methotrexate dose, mg/week* Concomitant oral prednisolone, n (%) In disease remission, n (%)## Start of INX, year, n 2000-2004 2005-2009 2010-2015 INX dose, mg/kg INX dose interval, weeks Prior INX treatment duration, years Prior INX treatment duration, years, mean (standard deviation) RA PsA AxSpA Total 602 418 (70) 62 (49-70) 167 (28) 1 (1-1) 491 (82) 15 (10-20) 57 (9) 343/558 (61) 167 79 (47) 50 (42-60) 42 (25) 1 (1-2) 123 (73) 15 (10-20) 11 (7) 83/154 (54) 352 96 (27) 46 (37-55) 60 (17) 1 (1-2) 118 (34) 12.5 (10-15) 9 (3) 88/319 (28) 1121 593 (53) 55 (44-66) 269 (24) 1 (1-1) 732 (65) 15 (10-20) 77 (7) 514/1031 (50) 119 (20) 299 (50) 184 (31) 3.3 (3.0-4.3) 8 (7-8) 5.8 (3.4-8.4) 6.0 (3.3) 15 (9) 82 (49) 70 (42) 4.8 (3.1-5.2) 8 (6-8) 4.8 (3.1-5.2) 4.8 (3.1) 44 (12) 176 (50) 132 (37) 4.8 (3.6-5.2) 8 (6-8) 5.0 (2.8-7.8) 5.2 (3.1) 178 (16) 557 (50) 386 (35) 3.8 (3.1-5.0) 8 (6-8) 5.3 (3.0-8.0) 5.6 (3.3) Numbers are medians (interquartile ranges) unless otherwise stated * Median dose of methotrexate per week among methotrexate treated patients #: the number of comorbidities was calculated according to the groups in the Charlson comorbidity index excluding musculoskeletal comorbidity ##: the numbers of patients with available data are shown as denominator. The time window is 32 weeks before/after January 1st 2014 Abbreviations: RA: rheumatoid arthritis, PsA: psoriatic arthritis, AxSpA: axial spondyloarthritis